Inventor · disambiguated record
Yanwen Fu
Also filed as: FU YANWEN
11 granted patents·14 pending applications·9 citations·filing 2003–2023
83Inventor score
Files withSORRENTO THERAPEUTICS INC18DOPPALAPUDI VENKATA RAMANA2BRADSHAW CURT W1HOPE CITY1UNIV LOUISIANA STATE1
Top patents by PatentIndex Score
25 records- 0187US10301395B2Chemically-locked bispecific antibodiesSORRENTO THERAPEUTICS INC·Filed 2016·Granted May 28, 2019·3 cites·14 claims
- 0272US8293714B2Anti-angiogenic compoundsDOPPALAPUDI VENKATA RAMANA·Filed 2009·Granted Oct 23, 2012·2 cites·33 claims
- 0371US2022144971A1Chemically-Locked Bispecific AntibodiesSORRENTO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0467US11267905B2Chemically-locked bispecific antibodiesSORRENTO THERAPEUTICS INC·Filed 2019·Granted Mar 8, 2022·0 cites·19 claims
- 0567US10799598B2Disulfide bridging conjugatesSORRENTO THERAPEUTICS INC·Filed 2018·Granted Oct 13, 2020·0 cites·18 claims
- 0666US10435479B2Chemically-locked bispecific antibodiesSORRENTO THERAPEUTICS INC·Filed 2015·Granted Oct 8, 2019·1 cites·9 claims
- 0765US8937048B2Anti-angiogenic compoundsDOPPALAPUDI VENKATA RAMANA·Filed 2012·Granted Jan 20, 2015·1 cites·22 claims
- 0864US10336829B2Intracellular delivery compoundsSORRENTO THERAPEUTICS INC·Filed 2016·Granted Jul 2, 2019·2 cites·29 claims
- 0963US10925968B2Cell internalizing compoundsSORRENTO THERAPEUTICS INC·Filed 2019·Granted Feb 23, 2021·0 cites·17 claims
- 1062US2025205350A1Antibody-Drug Conjugates and Uses ThereofVIVASOR INC·Filed 2023·Application pending·0 cites
- 1161US2021052738A1Disulfide Bridging ConjugatesSORRENTO THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1259US2021138075A1Cell internalizing compoundsSORRENTO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1358US2024181073A1Antibody-Drug Conjugates Comprising an Anti-BCMA AntibodySORRENTO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1455US2023416343A1Neutralizing Antibodies that Bind the SARS-COV-2 S ProteinSORRENTO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1554US2023096410A1Innate Immunity Killer Cells Targeting PSMA Positive Tumor CellsSORRENTO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1652US2023158125A1Pulmonary Administration of ACE2 PolypeptidesSORRENTO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1751US7345022B2Anti-fibril peptidesUNIV LOUISIANA STATE·Filed 2003·Granted Mar 18, 2008·0 cites·24 claims
- 1850US11607457B2Anti-cancer phosphorothioate-coupled peptide conjugates and methods of using the sameHOPE CITY·Filed 2018·Granted Mar 21, 2023·0 cites·11 claims
- 1946US2009098130A1Glucagon-like protein-1 receptor (glp-1r) agonist compoundsBRADSHAW CURT W·Filed 2008·Application pending·0 cites
- 2044US10583193B2Cell penetrating peptide inhibitors of p53-MDM2 interactionSORRENTO THERAPEUTICS INC·Filed 2018·Granted Mar 10, 2020·0 cites·12 claims
- 2143US2018194859A1Linked Dual Antibodies Conjugated at a Hinge RegionSORRENTO THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2242US2018280531A1C-met antibody drug conjugateSORRENTO THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 2342US2017281796A1c-Met Antibody Drug ConjugateZHU TONG·Filed 2015·Application pending·0 cites
- 2436US2016326266A1Chemically-Locked Bispecific AntibodiesSORRENTO THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 2534US2017112878A1Programmable universal cell receptors and method of using the sameSORRENTO THERAPEUTICS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yanwen Fu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →